Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(40%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
4
80%
Ph phase_3
1
20%

Phase Distribution

0

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
4(80.0%)
Phase 3Large-scale testing
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(3)

Detailed Status

Completed3
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (80.0%)
Phase 31 (20.0%)

Trials by Status

completed360%
recruiting240%

Recent Activity

2 active trials
Showing 5 of 5
recruitingphase_2

Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy

NCT05514340
recruitingphase_2

PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury

NCT04054414
completedphase_2

PMZ-1620 (Sovateltide) in Acute Ischemic Stroke Patients

NCT04046484
completedphase_3

Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke

NCT04047563
completedphase_2

PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease

NCT04052737

Clinical Trials (5)

Showing 5 of 5 trials
NCT05514340Phase 2

Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy

Recruiting
NCT04054414Phase 2

PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury

Recruiting
NCT04046484Phase 2

PMZ-1620 (Sovateltide) in Acute Ischemic Stroke Patients

Completed
NCT04047563Phase 3

Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke

Completed
NCT04052737Phase 2

PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5